Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor

Molecular Pharmacology

Volumn 63, Issue 1, 2003, Pages 192-202

  Tentori, Lucio ^a   Portarena, Ilaria ^a   Barbarino, Marcella ^a,c   Balduzzi, Alessandra ^e   Levati, Lauretta ^b   Vergati, Matteo ^c   Biroccio, Annamaria ^c   Gold, Barry ^d   Lombardi, Maria Luisa ^c   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; 3 METHYLADENINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RIBONUCLEOPROTEIN; TAMOXIFEN; TELOMERASE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL DIVISION; DACARBAZINE; DNA LIGASES; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MELANOMA; POLY(ADP-RIBOSE) POLYMERASES; SULFONES; TELOMERASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037220314     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.1.192     Document Type: Article

References (41)

1. Abrey LE and Christodoulou C (2001) Temozolomide for treating brain metastases. Semin Oncol 28:34-42.
2. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, and Ang KK (1997) Cutaneous melanoma, in Cancer: Principle and Practice of Oncology (DeVita VT Jr, Hellman S, Rosemberg SA eds) pp 1947-1994, Lippincott-Raven, Philadelphia.
3. Biasco G, Pantaleo MA, and Casadei S (2001) Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 345:621-622.
4. Biroccio A, Amodei S, Benassi B, Scarsella M, Cianciulli A, Mottolese M, Bufalo DD, Leonetti C, and Zupi G (2002) Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene 21:3011-3019.
5. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, and Zupi G (2001) c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 60:174-182.
6. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M, and Stevens MF (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, and Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
9. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3:837-847.
10. Encell L, Shuker DE, Foiles PG, and Gold B (1996) The in vitro methylation of DNA by a minor groove binding methyl sulfonate ester. Chem Res Toxicol 9:563-567.
11. Engelward BP, Allan JM, Dreslin AJ, Kelly JD, Wu MM, Gold B, and Samson LD (1998) A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J Biol Chem 273:5412-5418.
12. Faraoni I, Bonmassar E, and Graziani G (2000) Clinical applications of telomerase in cancer treatment. Drug Resist Updat 3:161-170.
13. Folini M, De Marco C, Orlandi L, Daidone MG, and Zaffaroni N (2000) Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur J Cancer 36:2137-2145.
14. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, and Weinberg RA (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170.
15. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963.
16. Kondo Y, Komata T, and Kondo S (2001) Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol 18:1287-1292.
17. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, and Cowell JK (1998) Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-2248.
18. Korabiowska M, Brinck U, Dengler H, Stachura J, Schauer A, and Droese M (2000) Analysis of the DNA mismatch repair proteins expression in malignant melanomas. Anticancer Res 20:4499-4505.
19. 6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 80:744-750.
20. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, and DePinho RA (2001) Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 98:3381-3386.
21. Liu L, Taverna P, Whitacre CM, Chatterjee S, and Gerson SL (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5:2908-2917.
22. Lo Muzio L, Nocini P, Mignogna MD, Pannone G, Staibano S, Procaccini M, Rubini C, Fioroni M, Fanali S, and Piattelli A (2000) Immunocytochemical detection of hMSH2 and hMLH1 expression in oral melanoma. Anticancer Res 20:741-748.
23. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, and von Zglinicki T (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-3061.
24. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, and Gilson E (2002) Natural and pharmacological regulation of telomerase. Nucleic Acids Res 30:839-865.
25. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166.
26. Morin GB (1989) The human telomere terminal transferase enzyme is a ribonuclo-protein that synthesizes TTAGGG repeats. Cell 59:521-529.
27. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, and Brock C (1997) Temo-zolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61.
28. Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, and Newbold RF (1999) Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer 79:47-53.
29. 6-alkylguanine by alkyltransferases. Mutat Res 462:83-100.
30. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE, and Shay JW (1995) Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17:1-15.
31. Pirozzi G, Lombari V, Zanzi D, Ionna F, Lombardi ML, Errico S, Ruggiero G, and Manzo C (2000) CD40 expressed on human melanoma cells mediates T cell costimulation and tumor cell growth. Int Immunol 12:787-795.
32. Tentori L, Balduzzi A, Portarena I, Levati L, Vernole P, Gold B, Bonmassar E, and Graziani G (2001a) Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ 8:817-828.
33. Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G (2002a) Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99:2241-2244.
34. 6-alkylguanine DNA-alkyltransferase or poly-(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258.
35. Tentori L, Portarena I, Bonmassar E, and Graziani G (2001b) Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ 8:457-469.
36. 3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother Pharmacol 49:217-224.
37. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, Bonmassar E, Graziani G (1999) Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13:901-909.
38. Tentori L, Vernole P, Lacal PM, Madaio R, Portarena I, Levati L, Balduzzi A, Turriziani M, Dande P, Gold B, et al. (2000) Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. Leukemia 14:1451-1459.
39. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74:1030-1036.
40. Zhang Y, Chen F-X, Metha P, and Gold B (1993) The design of groove and sequence selective alkylation of DNA by sulfonate esters tethered to lexitropsins. Biochemistry 32:7954-7965.
41. Zhang X, Mar V, Zhou W, Harrington L, and Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399.